[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"proximal-early-gastric-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:proximal-early-gastric-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100555401","the-anti-reflux-effect-of-double-flap-technique-in-laparoscopic-proximal-gastrectomy-100555401",false,"NCT06511609","The Anti-reflux Effect of Double-flap Technique in Laparoscopic Proximal Gastrectomy.","Comparison of Anti-reflux Effects of Laparoscopic Proximal Gastrectomy With Double-flap Technique (Kamikawa Anastomosis) Versus Double-tract Reconstruction: A Prospective, Multicenter, Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Age between 20 and 80 years, regardless of gender;\n2. Patients diagnosed with gastric cancer through tissue biopsy;\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n4. American Society of Anesthesiologists (ASA) classification of I to III;\n5. Acceptable for laparoscopic proximal gastrectomy with preoperative examinations (based on endoscopic ultrasound and\u002For contrast-enhanced computed tomography of the thorax and abdomen) confirming the following oncological features:\n\n   Primary tumor located in the upper part of the stomach (proximal 1\u002F3 of the stomach) or gastroesophageal junction; Length of esophageal invasion ≤ 1 cm, tumor maximum diameter ≤ 4 cm; Preoperative staging T1-3N0M0 (based on AJCC 8th edition TNM clinical staging);\n6. Voluntary signing of informed consent.\n\nExclusion Criteria:\n\n1. Received preoperative chemotherapy, radiotherapy, targeted therapy, or immunotherapy;\n2. Presence of contraindications to surgery;\n3. Multiple malignant lesions in the stomach;\n4. Presence of other malignancies that may affect the preservation of stomach function;\n5. Previous upper abdominal surgery (excluding cholecystectomy);\n6. Preoperative examination reveals active peptic ulcer;\n7. Patients who have received or are currently receiving treatment for systemic inflammatory diseases;\n8. Pregnant or breastfeeding women;\n9. Conditions deemed unsuitable for participation in this study by the investigator.","ALL","20 Years","80 Years",{"count":20,"type":21},244,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a multicenter, open-label, prospective, randomized parallel-controlled trial. The purpose is to explore whether the incidence rate of reflux esophagitis (RE) within 12 months after surgery is non-inferior for the DFT group compared to the DTR group.",[27],"Proximal Early Gastric Cancer","NOT_YET_RECRUITING","2024-07-15",{"date":31,"type":32},"2024-07-22","ACTUAL",{"date":34,"type":21},"2024-08-01",{"date":36,"type":21},"2027-07-31",{"name":38,"class":39},"Changzhi People's Hospital Affiliated to Changzhi Medical College","OTHER"]